VitalTrace has officially commenced its participation in the Texas Medical Center Innovation (TMCi) 2025 HealthTech Accelerator. Out of over 120 global applicants, we are proud to be one of just 12 companies selected—and among a very small number of international participants.
TMC is the largest healthcare provider in the United States and one of the largest globally. This opportunity has already yielded significant gains for the company, deepening our understanding of the U.S. hospital landscape. Discussions with leading institutions highlighted a consistent drive to reduce caesarean section rates, driven by strong fiscal and clinical imperatives.
Obstetricians and healthcare executives were candid in their support, emphasizing the urgent need for improved diagnostic tools. They shared that legal settlements related to hypoxic-ischemic encephalopathy can exceed US$40 million in Texas—and even higher in states like Massachusetts—underscoring the critical importance of innovation in this space.
We are immensely proud of the team’s efforts in preparing the company for this milestone, and we are deeply encouraged by the warm and validating reception we received in the U.S. We look forward to continuing our participation and contributing meaningfully to the program.
No items found.
No items found.
Using technology for better obstetric decision making
A wonderful feature from one of VitalTrace's clinical and commercial advisors, Vinayak Smith, on the role of innovative technologies to reduce the risk of litigation in obstetrics!
September 24, 2020
•
3 min read
A wonderful feature from one of VitalTrace's clinical and commercial advisors, Vinayak Smith, on the role of innovative technologies to reduce the risk of litigation in obstetrics!
“Cardiotocography (CTG) has been used for foetal heartrate (FHR) surveillance since the 1970s, as a means of detecting foetal hypoxia and guiding clinical decisions around delivery timing.
Despite the length of its usage, there is yet to be convincing evidence that CTG reduces birth asphyxia, stillbirths, caesareans or instrumental deliveries.
Although the technology is good at providing reassurance when foetal heartrates are ‘normal’, it is less useful at working out the prognosis of ‘abnormal’ heartrates, explains Dr. Vinayak Smith, of Monash University and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
“It is not easy for two clinicians to agree or interpret the same CTG output the same way,” said Dr. Smith ahead of the Obstetric Malpractice Conference.
“Heartrates which look normal are easy to trust, whereas abnormal ones could mean anything. The CTG doesn’t tell us how worried we should be when a heartrate doesn’t look quite right.
“As a result, FHR red flags can be wrongfully dismissed by the clinician, leading to ‘preventable’ delivery complications or, in extreme cases, foetal deaths.
“Conversely, false alarms can lead to unnecessary clinical intervention and greater numbers of (precautionary) C-sections – a procedure which is risky for both mother and baby.”
Aside from the risk of healthcare complications, CTG reliability issues expose clinicians to legal culpability.
With 20 percent of obstetrics claims involving CTG – and obstetrics accounting for a significant proportion of medico legal disputes – it is widely agreed that better foetal monitoring solutions are needed.”
No items found.
VitalTrace's first peer-reviewed journal article published in The SMFM Pregnancy Journal
Our first peer-reviewed journal article has been published in The SMFM Pregnancy Journal — the official open-access journal of the Society for Maternal-Fetal Medicine (SMFM) based in Washington, DC.
June 6, 2025
•
3 min read
Our first peer-reviewed journal article has been published in The SMFM Pregnancy Journal — the official open-access journal of the Society for Maternal-Fetal Medicine (SMFM) based in Washington, DC.
In collaboration with The University of Western Australia, our study demonstrates the capability of our technology, DelivAssure, in detecting early signs of fetal lactic acidosis, highlighted by the strong correlation between sensor current and venous blood lactate levels.
We're proud to contribute to the growing body of evidence aimed at improving outcomes for mothers and babies — DelivAssure has the potential to revolutionise intrapartum care by enabling crucial early detection and management of fetal asphyxia during labor and delivery.
📰 Read the full article here: https://onlinelibrary.wiley.com/doi/10.1002/pmf2.70017
We're incredibly grateful to our collaborators, clinical partners, and the SMFM editorial team for supporting this work.
No items found.
VitalTrace partners with IPREP in 2020
VitalTrace has had the pleasure of participating in iPREP WA's Industry and PhD Research and Engagement Program.
September 3, 2020
•
3 min read
VitalTrace has had the pleasure of participating in iPREP WA's Industry and PhD Research and Engagement Program. We were fortunate to work with our very own “Dream Team”; Alvin Lee, Saman Akbar Zadeh and Georgios Mavropalias, bringing their expertise in signal processing, data science and biomedical science respectively.